Improving the translation of novel biomarkers to clinical practice: The story of cystatin C implementation in Canada A professional practice column
Improving the translation of novel biomarkers to clinical practice: The story of cystatin C implementation in Canada A professional practice column
复制标题
DOI：
10.1016/j.clinbiochem.2017.01.005
复制
发表时间：
2017-05-01
影响因子：
2.8
通讯作者：
Filler, Guido
中科院分区：
文献类型：
--
作者：
Ismail, Ola Z.;Bhayana, Vipin;Filler, Guido
临床CysC检测仅限于加拿大的三个中心，落后于其他发达国家的举措。临床冠军在很大程度上对这种新的肾脏生物标志物的成功实施负有责任，这些冠军与实验室领导之间的个人关系和公开对话似乎是成功结果的先决条件。此外，评估价值交付的质量效益的上下文中进行比较
ConclusionsClinical CysC testing has been limited to only three centers in Canada, lagging behind initiatives seen in other developed nations. Clinician champions have been largely responsible for the successful implementation of this new renal biomarker, and it appears that personal relationships and an open dialogue between these champions and laboratory leadership are prerequisites for a successful outcome. Additionally, assessing the value delivered in the context of quality benefits compared to